For all press and media enquiries please contact mediarelations@chiesi.com
Key highlights: Successfully completed the TRECOS Phase III study*, supporting the long-term safety of Chiesi’s carbon minimal pressurized metered dose inhaler (pMDI) platform 1 Aiming to become the first pharmaceutical company to transition its broad pMDI portfolio to a next generation propellant,…
Positive first-half performance underpins full-year 2025 outlook; the Group highlights resilience amid the macro-economic headwinds while advancing its Patients-Planet-People-Prosperity strategy HIGHLIGHTS € 1.86 billion sales revenues, 13.2% organic growth at constant exchange rates (CER). EBITDA…
Parma, Italy and Villars-sur-Glâne SA, Switzerland, 11 August 2025 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative solutions for people living with rare diseases, announced today that FILSUVEZ® (Oleogel-S10, dry extract from birch bark) was…
Chiesi Group and Serna Bio have entered into a collaboration agreement to discover and develop novel small molecule drugs directed to respiratory diseases. The partnership will leverage Serna’s proprietary RNA-targeting small molecule discovery platform. Serna Bio's innovative technology enables the…
Key Highlights from 2024: Patients: Invested €829 million in R&D; opened Parma Biotech Center of Excellence; Health Equity initiatives now active in 33 countries; expanded efforts to improve access to neonatal treatments in low-income countries. Planet: Published Climate Transition Plan reinforcing…
Nazareth, Israel and Parma, Italy, June 05, 2025 – Elgan Pharma Ltd. and Chiesi Farmaceutici S.p.A today announced the dosing of the first participating infants in FIT-PIV, a Phase 3 clinical study to assess the efficacy and safety of ELGN-2112, an investigational drug candidate for treatment of…
HIGHLIGHTS €3.4 billion revenues, up 13% at constant exchange rates (CER) compared to 2023 Record R&D investment of €829 million (24.3% of revenues) Profitability close to 30% for the fifth consecutive year Air franchise: revenues of €1.8 billion, a growth of 7.2%% (CER). Fastest growing company…
The project is part of the Group’s industrial plan to support its global growth The site will specialize in the production of sterile biological products, DPI and carbon minimal inhalers for the treatment of respiratory diseases, with a primary focus on the latter The redevelopment of the facility…
Chiesi Group appoints Roch Doliveux, Paolo Pucci, and Daphne Quimi to further enhance Board capabilities and internationalize leadership These senior business leaders bring diverse expertise and international experience, strengthening governance and international best practices, whilst supporting…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
